Biomind Labs Inc. (NEO:BMND)

Canada flag Canada · Delayed Price · Currency is CAD
0.2050
-0.0300 (-12.77%)
May 27, 2026, 9:42 AM EST
Market Cap12.67M
Revenue (ttm)n/a
Net Income-1.24M
EPS-0.02
Shares Out n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,500
Open0.2150
Previous Close0.2350
Day's Range0.2050 - 0.2150
52-Week Range0.0100 - 0.3200
Beta7.51
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About Biomind Labs

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s disease; BMND06 is in Phase I clinical trial for treatment of morbid obesi... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Alejandro Antalich
Employees 5
Stock Exchange Cboe Canada
Ticker Symbol BMND

Financial Performance

Financial numbers in USD Financial Statements